The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One

Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study

E2086, a Selective Orexin Receptor Two Agonist: Study for Promoting Wakefulness in Patients With Narcolepsy Type One

Long-term Safety and Efficacy of Extended-release Once-nightly Sodium Oxybate for Narcolepsy in Patients not Currently Taking an Oxybate

Effects of Solriamfetol on Neuropsychological Outcomes in Patients With Obstructive Sleep Apnea in the Real-world SURWEY Study